0000000000247671

AUTHOR

Fabrice Ivanes

showing 2 related works from this author

Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial

2022

Abstract Aims The role of diuretics in patients with intermediate-risk pulmonary embolism (PE) is controversial. In this multicentre, double-blind trial, we randomly assigned normotensive patients with intermediate-risk PE to receive either a single 80 mg bolus of furosemide or a placebo. Methods and results Eligible patients had at least a simplified PE Severity Index (sPESI) ≥1 with right ventricular dysfunction. The primary efficacy endpoint assessed 24 h after randomization included (i) absence of oligo-anuria and (ii) normalization of all sPESI items. Safety outcomes were worsening renal function and major adverse outcomes at 48 hours defined by death, cardiac arrest, mechanical ventil…

Randomizationmedicine.medical_treatmentVentricular Dysfunction Right[SDV]Life Sciences [q-bio]Critical Care and Intensive Care MedicinePlacebolaw.inventionRandomized controlled trialDouble-Blind MethodlawFurosemidemedicineHumansDiureticsbusiness.industryFurosemideGeneral Medicinemedicine.diseasePulmonary embolismBlood pressureTreatment OutcomeAnesthesiaAcute DiseaseDiureticBolus (digestion)Cardiology and Cardiovascular MedicinebusinessPulmonary Embolismmedicine.drug
researchProduct

Temporal Trends in Transcatheter Aortic Valve Replacement in France

2017

Background - Transcatheter aortic valve replacement (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk. However, national data regarding procedural characteristics and clinical outcomes over time are limited. Objectives - The aim of this study was to assess nationwide performance trends and clinical outcomes of TAVR during a 6-year period. Methods - TAVRs performed in 48 centers across France between January 2013 and December 2015 were prospectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry. Findings were further compared with those reported from the FRANCE 2 (French Aortic National CoreValve and Edwa…

Aortic valvemedicine.medical_specialtymedicine.medical_treatmentnational registry030204 cardiovascular system & hematologyoutcomes03 medical and health sciences0302 clinical medicineValve replacementCardiac tamponadeMedicine030212 general & internal medicineComputingMilieux_MISCELLANEOUSAortic dissectionbusiness.industryMortality ratetransfemoralEuroSCORE[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseasepacemaker3. Good healthSurgeryStenosisCathetermedicine.anatomical_structureCardiology and Cardiovascular Medicinebusiness
researchProduct